Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05080192 · ClinicalTrials.gov registry record
Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate
A clinical trial of Covid19, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT05080192 is a study of Covid19 that has completed, run by University of Pennsylvania. The registered enrollment target is 12 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05080192, a study of Covid19, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN) trial is being executed. The trial is testing a short intervention (10 days of fenofibrate therapy) on 30-day outcomes in COVID-19. The overarching goal of this sub-study is to explore the impact of fenofibrate on key longer term phenotypes of vascular, cardiac and pulmonary health, integrated cardiopulmonary function, persistent/chronic symptoms and quality of life.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fenofibrate
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2022-05-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05080192
The ClinicalTrials.gov registry entry for NCT05080192 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (100% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05080192 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05080192 about?
NCT05080192 is a clinical study titled "Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate". The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN) trial is being executed. The trial is testing a short intervention (10 days of fenofibrate therapy) on 30-day outcomes in COVID-19. The overarching goal of this sub-study is to explore the impact of fenofibra...
What is the current status of trial NCT05080192?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2021-08-11. Estimated completion is 2022-05-10.
What conditions does trial NCT05080192 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT05080192?
The interventions under investigation include: Placebo (DRUG), Fenofibrate (DRUG).
Who is sponsoring clinical trial NCT05080192?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05080192 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
COVID-19 Vaccines International Pregnancy Exposure Registry
RECRUITING
-
COVID-19 Survivorship Registry
RECRUITING
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Conversations You Want About Corona Virus Disease (COVID-19)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.